Eikon Therapeutics Inc EIKN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer
Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics to Participate in Multiple Investor Conferences in November
Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress
Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress
Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
Trading Information
- Previous Close Price
- $5.39
- Day Range
- $4.95–5.39
- 52-Week Range
- $4.95–17.40
- Bid/Ask
- $5.10 / $5.70
- Shares Outstanding
- 54.19M
- Market Cap
- $279.06M
- Volume/Avg
- 477,208 / 577,592
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 384
- Website
- https://www.eikontx.com
Valuation
Metric | EIKN |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.73 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | EIKN |
|---|---|
Quick Ratio | 6.97 |
Current Ratio | 7.21 |
Interest Coverage | — |
Quick Ratio
EIKN
Profitability
Metric | EIKN |
|---|---|
Return on Assets (Normalized) | −45.10% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −174.64% |
Return on Assets
EIKN
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|v!mlTz | LOCK|$$>S | $135B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|HWw@F# | LOCK|!nbp | $99B | |||
| Moderna Inc MRNA | LOCK|g>#sw$ | LOCK|v% | $84B | |||
| argenx SE ADR ARGX | LOCK|tB?&!m | LOCK|<@ | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|$M?Hh< | LOCK|h! | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Hp>fv<< | LOCK|LZL# | $31B | |||
| Incyte Corp INCY | LOCK|DMKLP#^ | LOCK|s% | $24B | |||
| BioNTech SE ADR BNTX | LOCK|jtFZ^X% | LOCK|k% | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|#s@H?YS | LOCK|J<!qj | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&z@QLn | LOCK|^C^ | $15B |